Recently, the National Medical Products Administration approved multiple clinical trial applications for stem cell therapy products, covering indications such as knee cartilage repair and diabetic foot ulcers. According to statistics, as of June 2025, China has registered over 200 stem cell clinical research projects nationally, with approximately 30% entering Phase II or above. For example, a trial using umbilical cord mesenchymal stem cells for Parkinson's disease at a top-tier hospital in Shanghai has completed enrollment of 80 patients, showing a 65% improvement rate in motor function.
Additionally, an institution in Beijing has achieved preliminary results in treating type 2 diabetes with stem cells, with 8 out of 12 patients reducing insulin dosage by more than 50%. These advances are attributed to the revision of the "Measures for the Administration of Stem Cell Clinical Research" and the optimization of the approval process, enabling more innovative therapies to enter clinical use rapidly.
Background and Significance
As the core of regenerative medicine, the clinical application of stem cell therapy has long been a goal pursued by the medical community. China has continuously increased policy support and research investment, with national funding exceeding 5 billion yuan for stem cell research in 2024. This breakthrough is not only technical but also reflects the improvement of the regulatory system—the National Medical Products Administration has established a fast-track review channel, shortening the approval cycle for some stem cell products to 6 months.
This progress holds significant reference value for the global development of regenerative medicine, particularly in standardized preparation and quality control, where China has established strict industry standards to ensure the safety and efficacy of therapies.
Significance for International Patients
For international patients, China's stem cell therapies offer new treatment options, especially for conditions that respond poorly to traditional treatments, such as degenerative joint diseases and neurodegenerative disorders. Clinical trial programs in China may provide enrollment opportunities. For instance, Shanghai Changzheng Hospital is recruiting international patients for a spinal cord injury stem cell trial, with over 10 patients from the United States and Australia already enrolled.
However, international patients should note that not all programs are open to international participants, and it is essential to assess the risks and benefits of the trials, as well as understand related medical costs and insurance coverage.
How MeiJiaKang Can Help
As a cross-border medical platform, MeiJiaKang can assist international patients in connecting with top stem cell treatment centers in China. We provide cost estimation and medical services consultations, help patients screen suitable clinical trial programs, and arrange supporting services such as visas, translation, and follow-up care. Through our partner hospital network, patients can gain priority access to expert assessments and enrollment opportunities at top-tier hospitals in Shanghai and Beijing.
If you are interested in stem cell therapy, feel free to contact us, and our medical consultants will provide personalized advice based on your condition.
Related reading: List of Partner Hospitals in Shanghai